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Pharmacokinetics of doxorubicin co-administered with high-dose
verapamil
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Divirion ofExperinental Oncology 1, Centro d Riferimento Oncologico, Aviano (PN), Italy
Sy The potental for the m ion of the pharmacokinetics of doxorubicin (DOX) concurrently
administcred with highoe vramil (VER) has be investigated in 17 patients with advanced as s
refractory to drugs woning to the mulidrug resance spectrUmn Steady-state concentration of DOX,
systemic canc and urmary excton wer analysed. No sgnifcant difference was found betwen the
kinetic p s estimated for DOX at differt klve ofVER and those reported for doxorubicin as single
agenL It can be concded that VER does not appear to modify DOX kinetics.
WeywsrM doxorubicn MDR; pharmacokintc verpamil
Experimental data suggest that multidrug resistance (MDR)
in cancer may be overcome by using anti-cancer agents in
combination with resistance-modifying agents (RMAs) such
as verapamil (Tsuruo et al., 1983). Recently we demonstrated
that the best results in overcoming in vitro MDR to DOX
require continuous VER exposure, at concentrations >Ipm
and for a time roughly similar to the cells' repliation time
(Boiocchi and Toffoli, 1992; Toffoli et al., 1993). Based on
these in vitro results, we are trying to design clinical trials
based on a continuous infusion of DOX and VER, which
may be more effective than previous clinical trials. For this
purpose, knowledge of the consequences of the administra-
tion of RMAs on drug kinetics is fundamental. High-dose
cyclosporine, for example, produces significant increases in
etoposide systemic exposure (Lum et al., 1992). Results con-
cerning the kinetics of DOX modulated by VER are contro-
versial (Kerr et al., 1986). The purpose of the present study
was to verify the possible variation in the kinetics of DOX
concurrently mini with VER, infuse at escalating
dose rates throughout the DOX infusion. F ting dose
rates of VER infusion were plann to prevent sudden
cardiovascular toxicity resulting from the required, high VER
concentration. The prolonged infusion of DOX was seleted
because it offers, at kast in vitro (Lai et al., 1991), the
possibility of increasing tumoricadal effects based on neo-
plasms expressing P-glycoprotein (P-gp), such as colon car-
anoma. DOX at 75 mgm-2 was infused over % h (schedule
A) or 48 h (schedule B). This later schedule was ed to
ahev the target steady-state concentration (C.) of DOX at
the bnning of the infusion, simultaneously with higher
dose rates of VER infilsion.
M dateriak and
Patients
Seventeen subjects, eight males and nine females, were
included in this study. Median age was 42 years, ranging
from 21 to 67. Primary sites were colon (13 patients), rectum
(one patient), bone (one patient) and soft tissue (two
patients). No patient had congestive heart failure and none
had renal or liver dysfunction according to protocol
eligibility criteria. The therapeutic protocol was approved by
an ehical committee; the patents were informed of the
nature of the study and gave consent for the treatment
protocol.
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Adninistration ofdrugs
VER (Isoptin, Knoll) administration by a central vein
catheter started with a loading dose of 0.15 mg kg-' (tirm 0)
and continued for 132 h. The infusion schedule was as fol-
lows: 02, 0.25, 0.3, 0.35 and 0.4mgkg-' h-' at intervals of
0-12h, 12-36h, 36-60h, 60-84h and 84-132h respec-
tively. DOX was co- inistered following two schedules:
(A) the dose of DOX was 75 mgm-2 per course (from hour
12 to hour 108); (B) a loading dose of 29mgm-2 DOX was
given at hour 60;, subsequent maintenance infusion of
23 mgm2day-' lasted 48h, until hour 108. Blood samples
to measure DOX concentration were withdrawn at the fol-
lowing times: schedule A, hours 12, 24, 48, 60, 72, 96, 108,
132 and 144; schedule B, hours 60, 66, 72, 84, 108, 132 and
144. Urin were collcted at intervals of 12 h, from hour 0 to
hour 156. At least five samples were withdrawn after infusion
(from hour 108 to hour 168) in five patients following either
schedule A or B. Eeven patients followed schedule A, four
schedule B and two patients followed both schedules.
Drug assays
Serum and urine DOX concentrations were measured by
high-performance liquid chromatographic (HPLC) assay
(Zanette et al., 1990) with slight modifications. Daunorubicin
was added to each sample as the internal standard. The
efficiency of the extraction of DOX and daunorubicin
averaged 80% and 85% respectively. The assay was linear to
at least 10ngml'; interassay coefficient of variation ranged
from 5% to 15% at different concentrations.
Serum concentrations of VER and nor-verapamil (nor-
VER), an active RMA metabolite, were measured by HPLC
assay (Salama et al., 1989). Sampling of blood to measure
VER and nor-VER concentration was performed in all
patients, at least in the first course, at the following times:
hours 0, 12, 24, 36, 48, 60, 72, 84, 108, 132, 144 and 156.
Phamacokietic anaysis
In order to study the systm at steady state (SS), a linear
one-compartment model was adopted. Rate of infusion (k0)
was calculated as:
K. = C. x Cl
where C. is the target steady-state concentration (M/V) and
Cl is the apparent systemic clearance (Vlt) (mean value
reported in the literature; Benet and Widliams, 1990).
Observed C. was calulated in each patient as the mean
concentration of DOX on the last day of infision. No cor-
relation was found between concentration and time. The
mean C. was the mean value of observed concentrations
during the last day of infusion. The variability in C,. isKinetic modulaffon ofdoxorubicin byverapamil
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reported in Table I. The area under curve (AUC) was cal-
culated using the trapezoidal rule (data not shown).
The data do not represent the early distribution phase of
DOX after the onset of therapy or the late elimination
phase 2 or more days after infusion. On these grounds a
one-compartment model, with zero-order input and first-
order output, was identified a priori. Fitting of the model to
the data was good for almost all courses. The coefficient of
correlation between observed and calculated C. ranged from
0.7 to 0.99; the number of observations for each course
ranged from 6 to 14.
The distribution of DOX in the body is much faster than
elimination (Speth et al., 1988), thus the post-infusion curve
should very quickly approach the elimination phase curve.
Since the elimination of DOX is a first-order process and the
reported, final half-life of elimination is 30 h, three samples
were sufficient to estimate the constant of elimination (Eks-
borg et al., 1985). Individual ranges of variation of C., in
different courses are reported (Table I) only for the patients
who underwent several courses with schedule B, while most
patients following schedule A performed only one course.
PCNONLIN version 4.0 was the non-linear regression pro-
gram used to estimate kinetic parameters defining the model.
Statistical analysis
t-Tests for unpaired samples, with superimposable variability,
were performed to compare estimates of kinetic parameters
from groups of patients following different treatments.
Results
The observed C. was 23 ± 7ngml' (range 15-34ngml1)
for patients following schedule A (C3A) while the calculated
C. was 24 ngml-I (Table II). The observed C. for patients
following schedule B (C,B) was 35± 8 ngml-' (range
29-55ngml-') and calculated C. was 30ngml-'. Mean
(± s.d.) DOX concentrations of six patients for schedules A
and B are shown in Figure 1. The variability ofC. within the
first course and between different courses in patients follow-
ing schedule B is reported in Table I. Estimates of apparent
volume of distribution (V), half-life of elimination (t1) and
apparent systemic clearance (Cl), together with values
reported from the literature are reported in Table II. VA was
Table I Intra-patient variability of observed C. (schedule B)
Patient No. of, [DOXJ0 [DOX]b
no. courses first course (ngml-') (ngml-)
1 3 34 6 26-34
2 2 50±13 50-55
3 3 35 4 22-35
4 1 30 3 30
5 2 35 12 35-43
6 1 29 2 29
'Concentration observed on the second day (hour 84-108) of
infusion of DOX: mean ± s.d. bRange of C. in different courses.
21 ± 51 kg-' (range 16-27), VB was 20± 61 kg-' (range
17-31) and VL was 25 1 kg- (range 9-66); tiA was 20 ± 8 h
(range 14-32), tjB was 23 ± 5 h (range 16-29) and tlL was
30 h (range 14-37); CIA was 13 ± 4ml min' kg' (range
10-21), CIB was 13 ± 2mlmin-'kg-' (9-16) and ClL was
13 ml min' kg-' (range 8-16). The fractions of DOX ex-
creted in the urine (fu) were 9 ± 3% (A) and 7 ± 2% (B).
Individual parameters ranged from 3.7 to 11.2%. Estimates
of our study fell within the range reported in the literature
(fu< 15%) (Speth et al., 1990). Estimates of treatments A
and B were compared with each other and with reported
estimates (Benet and Williams, 1990): no significant
difference (P>0.6) was found.
On average, VER peak level was 1,650ngmml-' (ranging
from 620 to 2,560 ngml-') and serum concentrations of
nor-VER, a metabolite active as a chemosensitiser, were
590 ngml-' (ranging from 210 to 960 ngml-').
Cardiovascular side-effects were limited and rapidly rever-
sible after the completion of VER infusion. Data referred to
15 courses performed in nine patients. Prolonged QT was
observed in 15 courses (15/15); other side-effects were junc-
tional rhythm (9/15), first-degree block (4/15) and second-
degree block (1/15). No hypotension (mean arterial pressure
<80 mmHg) or congestive heart failure was observed. No
patient had hyperbilirubinaemia.
Discussion
The association of antineoplastic agents and RMAs requires
investigation of the possible kinetic variations in the drugs
resulting from their interaction. The few data available on
the interaction between VER and anthracyclines are contro-
versial. A significant increase in the half-life ofelimination of
DOX was found when DOX was co-administered with VER
(oral dose), but other kinetic parameters related to elimina-
tion did not differ significantly (Kerr et al., 1986). Scheithauer
et al. (1993) reported a significant decrease in the half-life of
epirubicin co-administered with D-VER; on the other hand,
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Figure 1 DOX concentrations in serum during and after 96 h
(0) and 48 h (0) infusion. Each point represents the mean value
(± s.d.) for six patients.
Table II Mean steady-state concentration (C.) of DOX, kinetic parameters of patients following
schedules A and B and parameters of DOX reported in the literature
Dox C.
time of infusion Patient Expected' Observed Vb tll Cld
Schedule (h) no. (ngml-') (ngml-') (Ikg-') (h) (mlmin ' kg-')
Ae 96 13 24 23+7' 21 ±5f 20+8' 13+4'
Be 48 6 30 36±8 20±6 23±5 13±2
25' 30 13
9-66h 14-37 8-16
aSee Materials and methods. 'Apparent volume of distribution. CHalf-life of elimination. dApparent
systemic clearance. CA, 96 h DOX i.v. infusion and 132 h high-dose VER infusion; B, bolus plus 48 h DOX
infusion and 132 h high-dose VER infusion. fMean ± s.d. 'Kinetic parameters of DOX reported in the
literature (Bennet and Williams, 1990). hRange of values reported in several studies (Speth et al., 1988).
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no variation in epirubicin kinetics was reported when
epirubicin was co-administered with VER (Mross et al.,
1993).
The results of the present study do not show significant
variations in the kinetics of DOX when concurrently
administered with VER. The unpaired data of this study
were compared with each other and with data from the
literature since ethical constraints prevented treatment of
patients without VER. In fact, 13 of the 17 patients analysed
had colon carcinoma, in which monochemotherapy with
DOX has no activity (Booser and Hrtobagy, 1994). The
unpaired data analysis not allow us to detect whether the
large inter-individual variations in DOX pharmacokinetics
we observed could mask small effects of VER on DOX
pharmacokinetics, if any. Nevertheless the robustness of the
conclusion of our study stands on the following features:
(1) Similar results were obtained from two different DOX
dosage regimens (schedules A and B).
(2) VER concentrations were continuous (e.g. concentrations
approaching C.) and relatively high, differently from
previous treatments with multiple oral dose (Kerr et al.,
1986); this regimen appears to be suitable to draw a
conclusion on the kinetic variation of DOX.
(3) This treatment was apparently well tolerated from the
haemodynamic point of view. Cardiovascular side-effects
were limited and reversible, so possible variations in the
pharmacokinetic parameters owing to impaired haemo-
dynamics were excluded.
(4) No borderline P-value was found comparing kinetic
parameters.
In conclusion, VER does not appear to modulate DOX
kinetics. These data should be considered in the design of
further schedules combining DOX with VER and the evalua-
tion of the response and toxicity determined by these
treatments to overcome MDR.
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